When was Olio Labs founded?

Olio Labs was founded in 2023 and raised its 1st funding round within a year of its incorporation.

Where is Olio Labs located?

Olio Labs is headquartered in United States.

How many employees does Olio Labs have?

As of Apr 30, 2026, the latest employee count at Olio Labs is 10.

Is Olio Labs a funded company?

Olio Labs is a funded company, having raised a total of $5M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2023.

When was the latest funding round of Olio Labs?

Olio Labs' latest funding was a $***** Series A round on Mar 20, 2025, with participation from 7 investors.

Where does Olio Labs rank among its competitors?

Olio Labs ranks 32nd amongst 71 active competitors, of which 40 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Profluent Bio, which secured $106M in Nov, 2025.

Who are the top competitors of Olio Labs?

Olio Labs' top competitors include Nimbus Therapeutics, Generate Biomedicines and Frontier Medicines. Among them, Profluent Bio secured the most recent funding round in November, 2025.

Olio Labs - 2026 Company Profile, Team, Funding & Competitors

Olio Labs is a series A company based in United States, founded in 2023 by David Tingley and Tom Roseberry. It operates as an AI-based drug development platform for combinational therapies. Olio Labs has raised $5M in funding from investors like Y Combinator, Boom Capital Ventures and Overwater Ventures. The company has 71 active competitors, including 40 funded and 5 that have exited. Its top competitors include companies like Nimbus Therapeutics, Generate Biomedicines and Frontier Medicines.

Company Details

AI-based drug development platform for combinational therapies. It focuses on designing drug combinations by considering the thousands of interacting proteins in the body rather than just targeting one or two.

Website: oliolabs.co
Email ID: *****@oliolabs.co

Key Metrics

Founded Year

2023

Location

United States

Stage

Series A

Total Funding

$5M in 2 rounds

Latest Funding Round

Series A, Mar 20, 2025, $*****

Investors

Y Combinator & 6 more

Ranked

32^nd among 71 active competitors

Employee Count

10 as on Apr 30, 2026

Similar Companies

Nimbus Therapeutics & 75 more

View Olio Labs' full profile

Olio Labs has raised a total funding of $5M over 2 rounds. Its first funding round was on 2023. Its latest funding round was a Series A round on Mar 20, 2025 for $*****. 7 investors participated in its latest round. Olio Labs has 7 institutional investors.

Here is the list of recent funding rounds of Olio Labs:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 20, 2025	6499292	Series A	1705947	4401116	6134569	9880287
2023	4594	Seed	1736	6960	Y Combinator	6128

Access funding benchmarks and valuations. Sign up today!

View details of Olio Labs's funding rounds and investors

The founders of Olio Labs are David Tingley and Tom Roseberry.

Here are the details of Olio Labs' key team members:

David Tingley: Co-Founder of Olio Labs.
Tom Roseberry: Co-Founder of Olio Labs.

View details of Olio Labs's Founder profiles and Board Members

Olio Labs' employee count trend

Olio Labs has 10 employees as of Apr 26. Here is Olio Labs's employee count trend over the years:

Uncover Olio Labs' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Olio Labs include Nimbus Therapeutics, Generate Biomedicines and Frontier Medicines. Here is the list of Top 10 competitors of Olio Labs, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, SR One & 20 others	69/100
2nd	Generate Biomedicines 2018, Somerville (United States), Public	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	NVentures, Pictet Group & 14 others	66/100
3rd	Frontier Medicines 2018, San Francisco (United States), Series C	Developer of a bioinformatics platform for drug development and chemoproteomics	$236M	Deerfield, RA Capital Management & 11 others	64/100
4th	Profluent Bio 2022, Berkeley (United States), Series B	Provider of an artificial intelligence-based protein design platform	$150M	Bezos Expeditions, Altimeter Capital & 6 others	64/100
5th	Cradle 2021, Delft (Netherlands), Series B	Provider of chemoproteomics solutions for protein design and development	$103M	Index Ventures, IVP & 7 others	64/100
6th	Seismic 2019, Watertown (United States), Series B	AI-assisted platform for drug discovery and development	$247M	Lightspeed Venture Partners, Bessemer Venture Partners ... & 12 others	62/100
7th	Eikon 2019, Millbrae (United States), Public	Protein tracking and measuring tool for drug discovery	$1.16B	The Column Group, AME Cloud Ventures & 22 others	62/100
8th	Vividion Therapeutics 2016, Oceanside (United States), Acquired	Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers	$271M	Boxer Capital, Logos & 20 others	61/100
9th	Orbit Discovery 2015, Oxford (United Kingdom), Series A	Developer of a drug discovery platforms by peptide display engine	$15.7M	Oxford Science Enterprises, Oxford University Innovation ... & 11 others	59/100
10th	Nomic 2017, Montreal (Canada), Series B	Provider of next-generation proteomics platform for drug discovery and protein analysis	$63M	Lux Capital, Amplitude & 13 others	57/100
32nd	Olio Labs 2023, United States, Series A	AI-based drug development platform for combinational therapies	$5M	Scrum Ventures, Y Combinator & 5 others	36/100